Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).
A live webcast of Mesoblast’s presentation can be accessed via either http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19955 or http://investorsmedia.mesoblast.com
The archived webcast will be available in the Events and Presentations section of the Company's website via www.mesoblast.com.
About Mesoblast
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.
For further information, please contact: Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected]
